News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/ped_ALL_pt_receiving_chemo_Bill_Branson_230.jpg)
FDA approves dasatinib for kids with Ph+ ALL
- Author:
- Jen Smith
The U.S.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/CTL019_Penn_Medicine_230.jpg)
Group proposes new grading systems for CRS, neurotoxicity
- Author:
- Jen Smith
A group of experts has proposed new consensus definitions and grading systems for cytokine release syndrome (CRS) and neurotoxicity related to...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/blood_for_transfusion_Credit_UAB_Hospital_230.jpg)
Drug may be new option for transfusion-dependent β-thalassemia
- Author:
- Jen Smith
SAN DIEGO—Luspatercept can produce “clinically meaningful” results in transfusion-dependent adults with β-thalassemia, according to a speaker at...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/richardson-paul-brt-230.jpg)
Melflufen-dex proves active in multi-resistant MM
- Author:
- Jen Smith
SAN DIEGO—The combination of melflufen and dexamethasone demonstrated activity in patients with multi-resistant multiple myeloma (MM) in a phase 2...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/Crowd_General-Session__ASH-2018_Photo-by-%C2%A9-ASH-Rodney-White-2018.jpg)
Lymphodepletion improves efficacy of CAR T cells in HL
- Author:
- Jen Smith
SAN DIEGO—A phase 1 study suggests lymphodepletion can improve the efficacy of CD30-directed chimeric antigen receptor (CAR) T-cell therapy in...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/crowd-ash-230.jpg)
Fludarabine deemed important for CD30.CAR T-cell therapy
- Author:
- Jen Smith
SAN DIEGO—Fludarabine is “very important” for lymphodepletion prior to CD30-directed chimeric antigen receptor (CAR) T-cell therapy, according to...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/Crowd_ASH-2018__Photo-courtesy-of-ASH.jpg)
MetS after HSCT linked to CV events, second cancers
- Author:
- Jen Smith
SAN DIEGO—Patients who develop metabolic syndrome (MetS) after hematopoietic stem cell transplant (HSCT) have an increased risk of cardiovascular...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/gotlib-jason-220.jpg)
Inhibitor can improve symptoms of systemic mastocytosis
- Author:
- Jen Smith
SAN DIEGO—The KIT D816V inhibitor avapritinib can improve symptoms of systemic mastocytosis (SM), according to researchers. Patients treated with...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/norsworthy-kelly-230.jpg)
Algorithm uncovers DS in AML patients on IDH inhibitors
- Author:
- Jen Smith
SAN DIEGO—An algorithm has proven effective for identifying differentiation syndrome (DS) in patients taking ivosidenib or enasidenib, according...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/gasparetto-cristina-230.jpg)
Triplet demonstrates activity in relapsed/refractory MM
- Author:
- Jen Smith
SAN DIEGO—A three-drug combination produced “deep and durable” responses in patients with relapsed/refractory multiple myeloma (MM), according to...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/Posters_ASH-2018_-_Photo-by-%C2%A9-ASH-Todd-Buchanan-2018.jpg)
Two-drug combo deemed ‘very promising’ for PMBCL
- Author:
- Jen Smith
SAN DIEGO—Nivolumab plus brentuximab vedotin may be a new treatment option for patients with relapsed/refractory primary mediastinal large B-cell...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/ASH18-aerial-scott-morgan-220.jpg)
Data support apixaban for cancer-associated VTE, doc says
- Author:
- Jen Smith
SAN DIEGO—Apixaban is as safe as, and more effective than, dalteparin for patients with cancer-associated venous thromboembolism (VTE), according...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/Crowd_ASH-2018__Photo-courtesy-of-ASH.jpg)
Regimen provides survival benefit in PTCL
- Author:
- Jen Smith
SAN DIEGO—A newly approved treatment regimen provides a survival benefit over standard therapy for patients with CD30-positive peripheral T-cell...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/venclexta-month-Abbvie-220.jpg)
FDA approves venetoclax for AML
- Author:
- Jen Smith
The U.S.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/AML_cells_Credit_Lance_Liotta_230.jpg)
FDA approves glasdegib for AML
- Author:
- Jen Smith
The U.S.